Cargando…

Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus

Contemporary SARS-Cov-2 pandemic, besides its dramatic global influence on the human race including health care systems, economies, and political decisions, opened a window for the global experiment with human vaccination employing novel injectable vaccines providing predominantly specific IgG respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Suvorov, Alexander, Gupalova, Tatiana, Desheva, Yulia, Kramskaya, Tatiana, Bormotova, Elena, Koroleva, Irina, Kopteva, Olga, Leontieva, Galina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823703/
https://www.ncbi.nlm.nih.gov/pubmed/35145407
http://dx.doi.org/10.3389/fphar.2021.807256
_version_ 1784646857016737792
author Suvorov, Alexander
Gupalova, Tatiana
Desheva, Yulia
Kramskaya, Tatiana
Bormotova, Elena
Koroleva, Irina
Kopteva, Olga
Leontieva, Galina
author_facet Suvorov, Alexander
Gupalova, Tatiana
Desheva, Yulia
Kramskaya, Tatiana
Bormotova, Elena
Koroleva, Irina
Kopteva, Olga
Leontieva, Galina
author_sort Suvorov, Alexander
collection PubMed
description Contemporary SARS-Cov-2 pandemic, besides its dramatic global influence on the human race including health care systems, economies, and political decisions, opened a window for the global experiment with human vaccination employing novel injectable vaccines providing predominantly specific IgG response with little knowledge of their impact on the mucosal immunity. However, it is widely accepted that protection against the pathogens at the gates of the infection - on mucosal surfaces—predominantly rely on an IgA response. Some genetically modified bacteria, including probiotics, represent attractive vehicles for oral or nasal mucosal delivery of therapeutic molecules. Probiotic-based vaccines for mucous membranes are easy to produce in large quantities; they have low cost, provide quite a long T-cell memory, and gut IgA response to oral vaccines is highly synchronized and strongly oligoclonal. Here we present a study demonstrating construction of the novel SARS-Cov-2 vaccine candidate employing the gene fragment of S1 SARS-Cov-2 gene. This DNA fragment was inserted in frame into major pili protein gene with d2 domain of enterococcal operon encoding for pili. The DNA sequencing proved the presence of the insert in enterococcal genome. RNA transcription, immunoprecipitation, and immune electron microscopy with human sera obtained from the SARS-Cov-2 patients demonstrated expression of SARS-Cov-2 antigens in bacteria. Taken together the data obtained allowed considering this genetically modified probiotic strain as an interesting candidate for vaccine against SARS-Cov-2.
format Online
Article
Text
id pubmed-8823703
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88237032022-02-09 Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus Suvorov, Alexander Gupalova, Tatiana Desheva, Yulia Kramskaya, Tatiana Bormotova, Elena Koroleva, Irina Kopteva, Olga Leontieva, Galina Front Pharmacol Pharmacology Contemporary SARS-Cov-2 pandemic, besides its dramatic global influence on the human race including health care systems, economies, and political decisions, opened a window for the global experiment with human vaccination employing novel injectable vaccines providing predominantly specific IgG response with little knowledge of their impact on the mucosal immunity. However, it is widely accepted that protection against the pathogens at the gates of the infection - on mucosal surfaces—predominantly rely on an IgA response. Some genetically modified bacteria, including probiotics, represent attractive vehicles for oral or nasal mucosal delivery of therapeutic molecules. Probiotic-based vaccines for mucous membranes are easy to produce in large quantities; they have low cost, provide quite a long T-cell memory, and gut IgA response to oral vaccines is highly synchronized and strongly oligoclonal. Here we present a study demonstrating construction of the novel SARS-Cov-2 vaccine candidate employing the gene fragment of S1 SARS-Cov-2 gene. This DNA fragment was inserted in frame into major pili protein gene with d2 domain of enterococcal operon encoding for pili. The DNA sequencing proved the presence of the insert in enterococcal genome. RNA transcription, immunoprecipitation, and immune electron microscopy with human sera obtained from the SARS-Cov-2 patients demonstrated expression of SARS-Cov-2 antigens in bacteria. Taken together the data obtained allowed considering this genetically modified probiotic strain as an interesting candidate for vaccine against SARS-Cov-2. Frontiers Media S.A. 2022-01-05 /pmc/articles/PMC8823703/ /pubmed/35145407 http://dx.doi.org/10.3389/fphar.2021.807256 Text en Copyright © 2022 Suvorov, Gupalova, Desheva, Kramskaya, Bormotova, Koroleva, Kopteva and Leontieva. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Suvorov, Alexander
Gupalova, Tatiana
Desheva, Yulia
Kramskaya, Tatiana
Bormotova, Elena
Koroleva, Irina
Kopteva, Olga
Leontieva, Galina
Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus
title Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus
title_full Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus
title_fullStr Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus
title_full_unstemmed Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus
title_short Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus
title_sort construction of the enterococcal strain expressing immunogenic fragment of sars-cov-2 virus
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823703/
https://www.ncbi.nlm.nih.gov/pubmed/35145407
http://dx.doi.org/10.3389/fphar.2021.807256
work_keys_str_mv AT suvorovalexander constructionoftheenterococcalstrainexpressingimmunogenicfragmentofsarscov2virus
AT gupalovatatiana constructionoftheenterococcalstrainexpressingimmunogenicfragmentofsarscov2virus
AT deshevayulia constructionoftheenterococcalstrainexpressingimmunogenicfragmentofsarscov2virus
AT kramskayatatiana constructionoftheenterococcalstrainexpressingimmunogenicfragmentofsarscov2virus
AT bormotovaelena constructionoftheenterococcalstrainexpressingimmunogenicfragmentofsarscov2virus
AT korolevairina constructionoftheenterococcalstrainexpressingimmunogenicfragmentofsarscov2virus
AT koptevaolga constructionoftheenterococcalstrainexpressingimmunogenicfragmentofsarscov2virus
AT leontievagalina constructionoftheenterococcalstrainexpressingimmunogenicfragmentofsarscov2virus